Non-Current Assets
Long-term marketable securities
Royalty Pharma Long-term marketable securities decreased by 2.9% to $406.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 85.8%, from $219.00M to $406.80M. Over 5 years (FY 2020 to FY 2025), Long-term marketable securities shows an upward trend with a 20.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
An increase indicates a long-term capital preservation strategy, while a decrease suggests the liquidation of long-term investments to fund operations or debt repayment.
Detailed definition
This represents long-term investments in debt securities that the company intends to hold for more than one year. These...
Peer comparison
Used by mature companies with strong cash flows to manage long-term liquidity and investment returns.
Metric ID:
non_current_assets_available_for_sale_securities_debt_se_908f76Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $202.50M | $188.68M | $204.40M | $239.60M | $63.00M | $339.80M | $226.30M | $267.20M | $343.70M | $353.60M | $437.10M | $473.70M | $629.90M | $657.30M | $693.50M | $219.00M | $271.90M | $302.50M | $419.00M | $406.80M |
| QoQ Change | — | -6.8% | +8.3% | +17.2% | -73.7% | +439.4% | -33.4% | +18.1% | +28.6% | +2.9% | +23.6% | +8.4% | +33.0% | +4.3% | +5.5% | -68.4% | +24.2% | +11.3% | +38.5% | -2.9% |
| YoY Change | — | — | — | — | -68.9% | +80.1% | +10.7% | +11.5% | +445.6% | +4.1% | +93.2% | +77.3% | +83.3% | +85.9% | +58.7% | -53.8% | -56.8% | -54.0% | -39.6% | +85.8% |
Range$63.00M – $693.50M
CAGR+15.8%
Avg YoY Growth+47.7%
Median YoY Growth+35.1%
Long-term marketable securities at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's long-term marketable securities?
- Royalty Pharma (RPRX) reported long-term marketable securities of $406.80M in Q1 2026.
- How has Royalty Pharma's long-term marketable securities changed year-over-year?
- Royalty Pharma's long-term marketable securities increased by 85.8% year-over-year, from $219.00M to $406.80M.
- What is the long-term trend for Royalty Pharma's long-term marketable securities?
- Over 5 years (2020 to 2025), Royalty Pharma's long-term marketable securities has grown at a 20.8% compound annual growth rate (CAGR), from $163.02M to $419.00M.
- What does long-term marketable securities mean?
- Long-term investments in debt securities held for interest income.